News Alert: Calif. 340B Health Centers Ask Judge to Stop Tomorrow’s “Devastating” State Medicaid Drug Payment Changes

California health centers asked U.S. District Judge John A. Mendez yesterday to stop a state Medicaid drug reimbursement change due to begin tomorrow that they say would strip away all their 340B drug discount savings.

California health centers asked a federal district judge yesterday to stop a major state Medicaid drug reimbursement change due to begin tomorrow. They say the change would strip away all their 340B drug discount savings, devastating safety-net health care

Read More »

Breaking News

Breaking News: AbbVie Becomes 11th Drug Maker to Restrict 340B Contract Pharmacy. Feds Appeal Rulings in Lilly, Novo Nordisk, and Sanofi Cases.

AbbVie is the 11th pharmaceutical maker to impose limits on 340B contract pharmacy.

Biopharmaceutical company AbbVie—maker of the expensive and widely prescribed immunosuppressive medication Humira—today became the 11th drug manufacturer to announce conditions on 340B pricing when contract pharmacies dispense medicines to patients.

Starting Feb. 1, AbbVie will require hospitals to submit claims

Read More »

Breaking News

Breaking News: Feds Appeal Rulings in Novartis and United Therapeutics 340B Contract Pharmacy Cases

The federal government yesterday asked the federal appeals court in Washington, D.C., to review a lower court's Nov. 5 joint ruling in Novartis and United Therapeutics' 340B contract pharmacy lawsuits.

The federal government late yesterday filed notice that it is appealing a federal judge’s joint ruling in two cases last month that halted enforcement actions against two drug companies that deny 340B pricing when hospitals and other health care providers

Read More »

John Thune, Senate’s No. 2 Republican and Strong 340B Provider Ally, Weighs Retirement

U.S. Senate Minority Whip John Thune (R-S.D.), a strong 340B covered entity ally, is considering not running for re-election in 2022. | Gage Skidmore/Flickr

South Dakota U.S. Sen. John Thune, the second-ranking Senate Republican and a long-time 340B covered entity ally, might not run for re-election in 2022, two news organizations report.  It would be a significant blow to 340B providers who have counted

Read More »

Manchin’s Idea that VA Negotiate Medicare Drug Prices Could Adversely Impact 340B Program, Expert Suggests

Congress should let the VA negotiate drug prices on behalf of Medicare, U.S. Sen. Joe Manchin (W.Va.) reportedly told the Senate Democratic Caucus this week.

U.S. Sen. Joe Manchin (D-W.Va.) has suggested that the U.S. Department of Veterans Affairs (VA) be empowered to negotiate drug prices on behalf of Medicare, an initiative that may impact the 340B program if it should come to fruition.


Read More »

Key Considerations to Reduce Impact of Contract Pharmacy Restrictions


Confucius once said that “roads were made for journeys, not destinations.” Hudson Headwaters has been at the forefront of the 340B journey for 20 years while continuously leveraging field-driven experience to help clients effectively navigate and manage their 340B involvement. Our goal is to prevent the 340B program model from reaching an

Read More »

Citing Omicron Wave, 340B Coalition Weighs Making Winter Conference a Hybrid Live/Virtual Event

Citing concerns about COVID-19's Omicron variant, the 340B Coalition is considering turning its Jan. 31–Feb. 2 in-person winter conference into a hybrid in-person/virtual event.

The 340B Coalition said yesterday it is “actively exploring the potential for a hybrid [winter 2022] conference that would allow attendance in-person or virtually for those that cannot attend in-person.”

The coalition, composed of 13 groups that represent 340B covered

Read More »

N.Y. and Va. Health Centers Say Discovery Should Continue in their Novel 340B-Related Federal Lawsuit

The federal district court for western New York is hearing two 340B health centers' antitrust lawsuit against insulin and diabetes drug makers.

New York State and Virginia health centers asked a federal district judge on Monday to deny four insulin and diabetes drug manufacturers’ motion to pause fact-finding in the health centers’ antitrust suit stemming from the companies’ 340B contract pharmacy policies.

Read More »

Novo Nordisk and Sanofi Have Jan. 26 Deadline to File Opening Briefs in 340B Contract Pharmacy Appeal

The U.S. Third Circuit Court of Appeals will hear Novo Nordisk and Sanofi's 340B contract pharmacy lawsuits in tandem, just as a lower court did.

A federal appeals court in Philadelphia has given drug manufacturers Novo Nordisk and Sanofi a Jan. 26 deadline to file briefs seeking reversal of parts of a district judge’s Nov. 5 joint decision in the two companies’ 340B contract pharmacy

Read More »

Boehringer Ingelheim Extends 340B Contract Pharmacy Restrictions to Previously Exempt Specialty Drug Ofev

Boehringer Ingelheim extended its restrictions on 340B drug sales to hospitals to Ofev, its expensive specialty drug for idiopathic pulmonary fibrosis.

Drug manufacturer Boehringer Ingelheim (BI) this month extended its restrictions on 340B drug sales to hospitals to Ofev, its expensive specialty drug for idiopathic pulmonary fibrosis.

BI announced its new 340B pricing policy in late June. Effective Aug.

Read More »